Clinical Trials Logo

Clinical Trial Summary

This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06184360
Study type Observational
Source Novartis
Contact
Status Completed
Phase
Start date May 31, 2022
Completion date December 16, 2022

See also
  Status Clinical Trial Phase
Completed NCT04126317 - Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration Phase 2
Completed NCT04847895 - Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
Active, not recruiting NCT05439629 - Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration Phase 3
Recruiting NCT05197270 - 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration Phase 1/Phase 2
Terminated NCT05473715 - A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment Phase 4
Recruiting NCT06346600 - A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD